Combination of ivosidenib plus venetoclax with or without azacitidine was well tolerated and effective in patients with IDH1-mutated hematologic malignancies.
Enasidenib plus azacitidine showed significantly improved response rates compared with azacitidine alone in patients with mIDH2 newly diagnosed acute myeloid leukemia.
Combined with azacytidine, the anti-CD47 antibody magrolimab was well tolerated and associated with promising activity in untreated patients with MDS and AML.
AMG 330, a CD33- and CD3-targeted bispecific T-cell engager appears safe and tolerable in dose-escalation study in patients with R/R AML.
In these additional analyses of CC-486 for patients with AML CC-486 was found to preserve health-related quality of life, be well tolerated and effective in older patients, and with dosing escalation improve response in patients with early relapse.
Pembrolizumab significantly improved PFS in patients with relapsed/refractory cHL vs brentuximab vedotin, including those ineligible for ASCT, with primary refractory disease, and who were brentuximab vedotin naive.
Zanubrutinib demonstrated a nonsignificant improvement in response rate and lower rates of several adverse events vs ibrutinib in patients with Waldenström macroglobulinemia.
Epcoritamab was associated with rapid, deep responses and low-grade CRS in heavily pretreated patients with R/R NHL.
Standard-risk younger patients with R/R cHL achieved high CMR with nivolumab plus brentuximab vedotin as first-line salvage therapy.
Extended follow-up data from multiple studies confirm significant efficacy and tolerability of acalabrutinib in CLL and other B-cell malignancies.
Weekly triplet regimen SVd significantly improved PFS compared with twice weekly Vd in multiple myeloma patients with 1-3 previous therapies
Belantamab mafodotin plus bortezomib/dexamethasone showed promising efficacy in heavily pretreated patients with RR myeloma.
Idecabtagene vicleucel therapy resulted in CR/sCR responses in one third of patients with heavily pretreated R/R MM with durability approaching 2 years.
BCMA-directed CAR T-cell therapy with orva-cel demonstrated robust activity in a dose-finding phase I study of heavily pretreated patients with multiple myeloma.
For newly diagnosed patients with multiple myeloma, adding RVD consolidation or a second ASCT to initial ASCT plus lenalidomide maintenance did not improve PFS or OS at 6 years for those with no progression at 38 months.
Addition of elotuzumab to RVd induction and maintenance therapy did not improve outcomes in patients with high-risk multiple myeloma
Venetoclax plus bortezomib/dexamethasone was selectively associated with favorable survival outcomes in patients with R/R myeloma and the t(11;14) cytogenetic marker in this updated study analysis.
In standard- or intermediate-risk patients with newly diagnosed MM who were not intended for early ASCT, KRd did not improve PFS compared with VRd